Poisons List Order 2001

2001. 

Acetic acid (excluding its salts and derivatives), and preparations containing more than 80% of acetic acid (CH₃COOH), for therapeutic use.

2002. 

Acetylcysteine in preparations for oral use except when labelled with a recommended daily dose of 1g or less of acetylcysteine.

2003. 

Aconitum spp. for therapeutic use in adults –

(a) in preparations for oral use in packs each containing 0.2mg or less of total alkaloids except in packs containing 0.02mg or less of total alkaloids; or

(b) in preparations for dermal use containing 0.02% or less of total alkaloids, in packs each containing 0.2mg or less of total alkaloids except in packs containing 0.02mg or less of total alkaloids.

2004. 

Aloxiprin.

2005. 

Amethocaine in preparations for topical use other than eye drops, containing 10% or less of total local anaesthetic substances, except in dermal preparations containing 2% or less of total local anaesthetic substances.

2006. 

Amorolfine for topical use in preparations containing 0.25% or less of amorolfine except in preparations for the treatment of tinea pedis.

2007. 

Antazoline in eye drops.

2008. 

Aspirin except –

(a) when included in Schedule 4 , 5 or 6 ; or

(b) in individually wrapped powders or sachets of granules each containing 650mg or less of aspirin as the only therapeutically active constituent other than an effervescent agent when –

(i) enclosed in a primary pack that contains not more than 12 such powders or sachets of granules; and

(ii) compliant with the Required Advisory Statements for Medicine Labels; or

(c) in tablets or capsules each containing no other therapeutically active constituent other than an effervescent agent when –

(i) packed in blister or strip-packaging or in a container with a child-resistant closure; and

(ii) in a primary pack of not more than 25 tablets or capsules, each containing 325mg or less of aspirin, or in a primary pack of not more than 16 tablets or capsules, each containing 500mg or less of aspirin; and

(iii) compliant with the requirements of the Required Advisory Statements for Medicine Labels; or

(d) in tablets or capsules each containing no other therapeutically active constituent other than an effervescent agent when –

(i) packed in blister or strip-packaging or in a container with a child-resistant closure; and

(ii) in a primary pack containing not more than 100 tablets or capsules, each containing 100mg or less of aspirin when packed and labelled for the prevention of cardiovascular disease or for the inhibition of platelet aggregation; and

(iii) compliant with the requirements of the Required Advisory Statements for Medicine Labels.

2008M. 

Atropa Belladonna (belladonna) –

(a) for external use in preparations containing 0.03% or less of total solanaceous alkaloids; or

(b) for oral use –

(i) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2mg or less of total solanaceous alkaloids; or

(ii) in divided preparations containing 0.3mg or less of total solanaceous alkaloids per dosage unit, when labelled with a recommended daily dose of 1.2mg or less of total solanaceous alkaloids.

2009. 

Atropine (excluding atropine methonitrate) for oral use –

(a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2mg or less of total solanaceous alkaloids.

2010. 

Azelaic acid in dermal preparations.

2011. 

Azelastine in preparations for nasal use.

2011M. 

Beclomethasone in aqueous nasal sprays delivering 50 micrograms or less of beclomethasone per actuation, when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

2013. 

Benzocaine in preparations for topical use other than eye drops –

(a) containing 10% or less of total local anaesthetic substances, except in dermal preparations containing 2% or less of total local anaesthetic substances; or

(b) in divided preparations containing 200mg or less of total local anaesthetic substances per dosage unit, except in lozenges containing 30mg or less of total local anaesthetic substances per dosage unit.

2014. 

Benzoyl peroxide in preparations for human external therapeutic use containing 10% or less of benzoyl peroxide, except in preparations containing 5% or less of benzoyl peroxide.

2015. 

Benzydamine in preparations for topical use, except in preparations for dermal use.

2016. 

Bephenium salts.

2017. 

Bifonazole in preparations for dermal use, except in preparations –

(a) containing 1% or less of bifonazole for the treatment of the scalp; or

(b) for the treatment of tinea pedis.

2018. 

Bromhexine.

2019. 

Brompheniramine when combined with one or more other therapeutically active substances in oral preparations when –

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day-night pack containing brompheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper –

except in preparations for the treatment of children under 2 years of age.

2019M. 

Budesonide in aqueous nasal sprays delivering 50 micrograms or less of budesonide per actuation, when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

2020. 

Carbetapentane except in preparations containing 0.5% or less of carbetapentane.

2021. 

Carbocisteine.

2022. 

Cetirizine in preparations for oral use.

2023. 

Chlophedianol.

2024. 

Chlorbutol for human use in topical preparations containing 5% or less of chlorbutol, except in preparations containing 0.5% or less of chlorbutol.

2025. 

Chloroform (excluding its derivatives) in preparations for therapeutic use except –

(a) when included in Schedule 4 ; or

(b) in preparations containing 0.5% or less of chloroform.

2026. 

Chlorpheniramine when combined with one or more other therapeutically active substances in oral preparations when –

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day-night pack containing chlorpheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper –

except in preparations for the treatment of children under 2 years of age.

2027. 

Ciclopirox in preparations for dermal use and for application to the nails containing 2% or less of ciclopirox, except in preparations for the treatment of tinea pedis.

2028. 

Cinchocaine in preparations for topical use other than eye drops, containing 0.5% or less of total local anaesthetic substances.

2029. 

Cinnamedrine.

2030. 

Clotrimazole for human use in dermal preparations and for application to the nails, except in preparations for the treatment of tinea pedis.

2031. 

Codeine when –

(a) compounded –

(i) with a single non-opiate analgesic substance in tablets or capsules each containing 10mg or less of codeine when –

(A)  packed in blister or strip packaging or in a container with a child-resistant closure; and

(B)  in a primary pack containing 25 or less dosage units; or

(ii) with a single non-opiate analgesic substance in individually wrapped powders each containing 10mg or less of codeine when in a primary pack containing 25 or less dosage units; or

(iii) with one or more other therapeutically active substances –

(A)  in divided preparations each containing 10mg or less of codeine; or

(B)  in undivided preparations containing 0.25% or less of codeine; and

(b) labelled with a recommended daily dose not exceeding 60mg of codeine.

2032. 

Creosote derived from wood other than beechwood for human therapeutic use, except in preparations containing 10% or less of creosote derived from wood other than beechwood.

2033. 

Datura spp. for oral use –

(a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2mg or less of total solanaceous alkaloids –

except when separately specified in these Schedules.

2033D. 

Datura stramonium (stramonium). for oral use when –

(a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2mg or less of total solanaceous alkaloids –

except for smoking or burning.

2033H. 

Datura tatula (stramonium). for oral use –

(a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2mg or less of total solanaceous alkaloids –

except for smoking or burning.

2034. 

Delphinium staphisagria except in preparations containing 0.2% or less of delphinium staphisagria.

2034M. 

Desloratadine in preparations for oral use.

2035. 

Dexchlorpheniramine when combined with one or more other therapeutically active substances in oral preparations when –

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day-night pack containing dexchlorpheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper –

except in preparations for the treatment of children under 2 years of age.

2036. 

Dextromethorphan (excluding its stereoisomers) when supplied in a pack containing 600mg or less of dextromethorphan and with a recommended daily dose of 120mg or less of dextromethorphan.

2037. 

Dibromopropamidine for ophthalmic use.

2037M. 

Diclofenac in divided preparations for oral use containing 12.5mg or less of diclofenac per dosage unit in a pack containing 20 or fewer dosage units and labelled with a recommended daily dose of 75mg or less of diclofenac.

2039. 

Dihydrocodeine when compounded with aspirin and no other therapeutically active substances in divided preparations –

(a) containing 5mg or less of dihydrocodeine per dosage unit; and

(b) packed in blister or strip packaging or in a container with a child-resistant closure; and

(c) enclosed in primary packs containing 25 or less dosage units; and

(d) labelled with a recommended dose not exceeding 10mg of dihydrocodeine.

2040. 

Dimenhydrinate in primary packs of 10 doses or less, for the prevention or treatment of motion sickness, except in preparations for the treatment of children who have not attained 2 years of age.

2041. 

Diphenhydramine in oral preparations –

(a) in a primary pack containing 10 dosage units or less, for the prevention or treatment of motion sickness; or

(b) when combined with one or more other therapeutically active substances when –

(i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(ii) in a day-night pack containing diphenhydramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper –

except in preparations for the treatment of children under 2 years of age.

2043. 

Doxylamine when combined with one or more other therapeutically active substances in oral preparations when –

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day-night pack containing doxylamine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper –

except in preparations for the treatment of children under 2 years of age.

2044. 

Duboisia leichhardtii for oral use –

(a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2mg or less of total solanaceous alkaloids.

2045. 

Duboisia myoporoides for oral use –

(a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3mg or less of the alkaloids of total solanaceous alkaloids and a recommended daily dose of 1.2mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2mg or less of total solanaceous alkaloids.

2046. 

Econazole for human use in dermal preparations, except in preparations for the treatment of tinea pedis.

2047. 

Etafedrine.

2048. 

Ether for therapeutic use except –

(a) when included in Schedule 4 ; or

(b) in preparations containing 10% or less of ether.

2049. 

Ethylmorphine when –

(a) compounded with one or more other therapeutically active substances –

(i) in divided preparations containing 10mg or less of ethylmorphine per dosage unit; or

(ii) in undivided preparations containing 0.25% or less of ethylmorphine; and

(b) labelled with a recommended dose not exceeding 15mg of ethylmorphine.

2050. 

Etofenamate in preparations for external use.

2051. 

Famotidine when sold in the manufacturer's original pack containing not more than 14 days' supply.

2052. 

Felbinac in preparations for external use.

2053. 

Fexofenadine in preparations for oral use.

2054. 

Fluorides for human use –

(a) in preparations for ingestion containing 0.5mg or less of fluoride ion per dosage unit; or

(b) in liquid preparations for topical use containing 1 000mg/kg or less of fluoride ion, in a container with a child-resistant closure –

(i) for therapeutic use when compliant with the requirements of the Required Advisory Statements for Medicine Labels (September 2008), except in preparations containing 220mg/kg or less of fluoride ion, in packs containing not more than 120mg total fluoride, when fitted with a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels; or

(ii) for non-therapeutic use when labelled with warnings to the following effect:

(A) Do not swallow;

(B) Do not use [this product/name of product] in children 6 years of age or less –

except in preparations containing 220mg/kg or less of fluoride ion, in packs containing not more than 120mg total fluoride, when fitted with a child-resistant closure and labelled with warnings to the following effect:

(A) Do not swallow;

(B) Do not use [this product/name of product] in children 6 years of age or less –

except in preparations containing 15mg/kg or less of fluoride ion or preparations for supply to registered dental professionals or by approval of an appropriate authority.

2054F. 

Flurbiprofen in divided preparations for topical oral use containing 10mg or less of flurbiprofen per dosage unit.

2054J. 

Fluticasone in aqueous nasal sprays delivering 50 micrograms or less of fluticasone per actuation, when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

2054M. 

Folic acid for human therapeutic use except –

(a) when included in Schedule 4 ; or

(b) in preparations containing 500 micrograms or less of folic acid per recommended daily dose.

2054S. 

Folinic acid for human therapeutic use except –

(a) when included in Schedule 4 ; or

(b) in preparations containing 500 micrograms or less of folinic acid per recommended daily dose.

2055. 

Formaldehyde (excluding its derivatives) for human therapeutic use except –

(a) in oral hygiene preparations containing 0.1% or less of free formaldehyde; or

(b) in other preparations containing 0.2% or less of free formaldehyde.

2056. 

Gelsemium sempervirens.

2057. 

Glutaraldehyde for human therapeutic use.

2060. 

Hexachlorophane in preparations for human use containing 3% or less of hexachlorophane except –

(a) in preparations containing 0.75% or less of hexachlorophane; or

(b) in preparations for use on infants, as specified in Schedule 4 .

2061. 

Hydrocortisone and Hydrocortisone acetate, but excluding other salts and derivatives, in preparations for human therapeutic use containing 0.5% or less of hydrocortisone –

(a) for dermal use, in packs containing 30g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or

(b) for rectal use when combined with a local anaesthetic substance but no other therapeutically active constituent except an unscheduled astringent –

(i) in undivided preparations, in packs of 35g or less; or

(ii) in packs containing 12 or fewer suppositories.

2062. 

Hydroquinone (excluding monobenzone and other alkyl ethers of hydroquinone included in Schedule 4 ) in preparations for human external therapeutic use or cosmetic use containing 2% or less of hydroquinone except hair preparations containing 1% or less of hydroquinone.

2063. 

8-hydroxyquinoline, and its non-halogenated derivatives, for human therapeutic use, except in preparations for external use containing 1% or less of such substances.

2064. 

Hyoscine (excluding hyoscine butylbromide) –

(a) for transdermal use in preparations containing 2mg or less of total solanaceous alkaloids per dosage unit; or

(b) for oral use –

(i) in undivided preparations containing 0.03% or less of total solanaceous alkaloids, when labelled with a dose of 0.3mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2mg or less of total solanaceous alkaloids; or

(ii) in divided preparations containing 0.3mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2mg or less of total solanaceous alkaloids.

2065. 

Hyoscine butylbromide, as the only therapeutically active substance, in divided preparations for oral use containing 20mg or less of hyoscine butylbromide per dosage unit in a pack containing 200mg or less of hyoscine butylbromide.

2066. 

Hyoscyamine –

(a) for external use in preparations containing 0.03% or less of total solanaceous alkaloids; or

(b) for oral use –

(i) in undivided preparations containing 0.03% or less of total solanaceous alkaloids, when labelled with a dose of 0.3mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2mg or less of total solanaceous alkaloids; or

(ii) in divided preparations containing 0.3mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2mg or less of total solanaceous alkaloids.

2067. 

Hyoscyamus niger for oral use –

(a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2mg or less of total solanaceous alkaloids –

except in a pack containing 0.03mg or less of total solanaceous alkaloids.

2068. 

Ibuprofen in preparations for oral use when labelled with a recommended daily dose of 1 200mg or less of ibuprofen –

(a) in liquid preparations when sold in the manufacturer's original pack containing 4g or less of ibuprofen; or

(b) in divided preparations, each containing 200mg or less of ibuprofen, in packs of not more than 100 dosage units except when –

(i) present as the only therapeutically active constituent other than an effervescent agent; and

(ii) packed in blister or strip-packaging or in a container with a child-resistant closure; and

(iii) in a primary pack of not more than 25 dosage units; and

(iv) not labelled for the treatment of children 6 years of age or less; and

(v) compliant with the Required Advisory Statements for Medicine Labels.

2069. 

Indanazoline.

2070. 

Indomethacin in preparations for external use containing 1% or less of indomethacin.

Iodine –

(a) in preparations for human internal therapeutic use containing 300 micrograms or more of iodine per recommended daily dose; or

(b) in preparations for human external therapeutic use containing more than 2.5% of available iodine (excluding salts, derivatives and iodophors).

2072. 

Ipratropium in preparations for nasal use.

2073. 

Iron compounds (excluding iron oxides when present as an excipient in divided preparations containing 10mg or less of total iron oxides per dosage unit or in undivided preparations containing 1% or less of total iron oxides) for human internal use except –

(a) when included in Schedule 4 ; or

(b) when labelled with a recommended daily dose not exceeding 24mg of iron –

(i) in undivided preparations supplied in packs each containing 750mg or less of iron; or

(ii) in divided preparations –

(A)   containing more than 5mg of iron per dosage unit in packs each containing 750mg or less of iron; or

(B)   containing 5mg or less of iron per dosage unit.

2074. 

Isoconazole for human use in dermal preparations.

2075. 

Isopropamide in preparations containing 2% or less of isopropamide for dermal use.

2076. 

Ketoconazole in preparations for dermal use, except in preparations –

(a) containing 1% or less of ketoconazole for the treatment of the scalp; or

(b) for the treatment of tinea pedis.

2077. 

Ketotifen for ophthalmic use in preparations containing 0.025% or less of ketotifen.

2078. 

Levocabastine in topical eye or nasal preparations.

2079. 

Lignocaine in preparations for topical use other than eye drops –

(a) containing 10% or less of total local anaesthetic substances, except in dermal preparations containing 2% or less of total local anaesthetic substances; or

(b) in divided preparations containing 200mg or less of total local anaesthetic substances per dosage unit, except in lozenges containing 30mg or less of total local anaesthetic substances per dosage unit.

2080. 

Lindane in preparations for human external therapeutic use containing 2% or less of lindane.

2081. 

Lithium in preparations for dermal use containing 1% or less of lithium except –

(a) when present as an excipient at 0.25% or less of lithium; or

(b) in preparations containing 0.01% or less of lithium.

2082. 

Lobelia inflata except for smoking or burning.

2083. 

Lobeline except in preparations for smoking or burning.

2084. 

Lodoxamide in preparations for ophthalmic use.

2085. 

Loperamide in preparations for oral use in packs of 20 dosage units or less.

2086. 

Loratadine in preparations for oral use.

2087. 

Mebendazole for human therapeutic use.

2087J. 

Meclozine in primary packs containing 12 or less tablets or capsules of meclozine for the prevention or treatment of motion sickness, except in preparations for the treatment of children under 2 years of age.

2088. 

Mefenamic acid in divided preparations for oral use in packs of 30 or less dosage units for the treatment of dysmenorrhoea.

2088M. 

Mepyramine for dermal use.

2090. 

Mercury for external use in preparations containing 0.5% or less of mercury.

2091. 

Methoxamine in preparations for external use except in preparations containing 1% or less of methoxamine.

2092. 

Methoxyphenamine.

2093. 

Methylephedrine.

2094. 

Miconazole for human use in dermal preparations and for application to the nails except in preparations for the treatment of tinea pedis.

2094M. 

Minoxidil in preparations for dermal use containing 5% or less of minoxidil.

2094R. 

Mometasone in aqueous nasal sprays delivering 50 micrograms or less of mometasone per actuation when the maximum recommended daily dose is no greater than 200 micrograms for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

2095. 

Naphazoline.

2096. 

Naproxen in divided preparations containing 250mg or less of naproxen per dosage unit in packs of 30 or less dosage units.

2097. 

Niclosamide for human therapeutic use.

2098. 

Nicotine for use as an aid in withdrawal from tobacco smoking in preparations for inhalation.

2098M. 

Nizatidine when sold in the manufacturer's original pack containing not more than 14 days' supply.

2099. 

Noscapine.

2100. 

Nystatin in dermal preparations.

2101. 

Oxetacaine (oxethazaine) in preparations for internal use.

2101M. 

Oxiconazole for dermal use except in preparations for the treatment of tinea pedis.

2102. 

Oxymetazoline.

2103. 

Papaverine except when included in Schedule 4 .

2104. 

Paracetamol for therapeutic use except –

(a) when included in Schedule 4 ; or

(b) in individually wrapped powders or sachets of granules each containing 1 000mg or less of paracetamol as the only therapeutically active constituent (other than phenylephrine or when combined with effervescent agents) when –

(i) enclosed in a primary pack that contains not more than 12 such powders or sachets of granules; and

(ii) compliant with the requirements of the Required Advisory Statements for Medicine Labels; and

(iii) not labelled for the treatment of children 6 years of age or less; and

(iv) not labelled for the treatment of children under 12 years of age when combined with phenylephrine; or

(c) in tablets or capsules each containing 500mg or less of paracetamol as the only therapeutically active constituent (other than phenylephrine or when combined with effervescent agents) when –

(i) packed in blister or strip packaging or in a container with a child-resistant closure; and

(ii) in a primary pack containing not more than 25 tablets or capsules; and

(iii) compliant with the requirements of the Required Advisory Statements for Medicine Labels; and

(iv) not labelled for the treatment of children 6 years of age or less; and

(v) not labelled for the treatment of children under 12 years of age when combined with phenylephrine.

2105. 

Paraformaldehyde (excluding its derivatives) for human therapeutic use except –

(a) in oral hygiene preparations containing 0.1% or less of free formaldehyde; or

(b) in other preparations containing 0.2% or less of free formaldehyde.

2106. 

Penciclovir for external use for the treatment of herpes labialis.

2107. 

Phedrazine.

2108. 

Phenazone for human external use.

2109. 

Pheniramine –

(a) in eye drops; or

(b) when combined with one or more other therapeutically active substances in oral preparations when –

(i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(ii) in a day-night pack containing pheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper –

except in preparations for the treatment of children under 2 years of age.

2110. 

Phenol, or any homologue of phenol boiling below 220°C, for human therapeutic use except –

(a) when included in Schedule 4 ; or

(b) in preparations for external use containing 3% or less of such substances.

2111. 

Phenylephrine except –

(a) when included in Schedule 4 ; or

(b) in oral preparations containing 50mg or less of phenylephrine per recommended daily dose in packs containing 250mg or less of phenylephrine; or

(c) in topical eye or nasal preparations containing 1% or less of phenylephrine.

2112. 

Pholcodine –

(a) in liquid preparations containing 0.5% or less of pholcodine and with a recommended dose not exceeding 25mg of pholcodine; or

(b) when compounded with one or more other therapeutically active substances, in divided preparations containing 10mg or less of pholcodine per dosage unit and with a recommended dose not exceeding 25mg of pholcodine.

2113. 

Piperazine for human therapeutic use.

2114. 

Podophyllotoxin in preparations containing 0.5% or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts.

2115. 

Podophyllum emodi (podophyllin) in preparations containing 10% or less of podophyllin for human use for the treatment of warts other than anogenital warts.

2116. 

Podophyllum peltatum (podophyllin) in preparations containing 10% or less of podophyllin for human use for the treatment of warts other than anogenital wars.

2117. 

Potassium chlorate for therapeutic use except in preparations containing 10% or less of potassium chlorate.

2118. 

Prilocaine in preparations for dermal use containing 10% or less of total local anaesthetic substances.

2119. 

Procyclidine in preparations containing 5% or less of procyclidine for dermal use.

2120. 

Promethazine in oral preparations –

(a) in a primary pack containing 10 dosage units or less, for the prevention or treatment of motion sickness; or

(b) when combined with one or more other therapeutically active substances when –

(i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(ii) in a day-night pack containing promethazine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper –

except in preparations for the treatment of children under 2 years of age.

2121. 

Propamidine for ophthalmic use.

2123. 

Pyrantel for human therapeutic use.

2123F. 

Pyrethrins, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids, for human therapeutic use in preparations containing more than 10% of such substances.

2124. 

Pyrithione zinc for human therapeutic use, except in preparations for the treatment of the scalp containing 2% or less of pyrithione zinc when compliant with the requirements of the Required Advisory Statements for Medicine Labels.

2125. 

Ranitidine in preparations supplied in the manufacturer's original pack containing not more than 14 days' supply, except when supplied as divided preparations for oral use containing 150mg or less of ranitidine per dosage unit in the manufacturer's original pack containing not more than 14 dosage units.

2126. 

Salicylamide except when included in Schedule 4 .

2126F. 

Selenium in preparations for human therapeutic use, except –

(a) for topical use containing 3.5% or less of selenium sulfide; or

(b) when included in Schedule 4 ; or

(c) for oral use with a recommended daily dose of 150 micrograms or less.

2127. 

Silver for therapeutic use except –

(a) in solutions for human oral use containing 0.3% or less of silver when compliant with the requirements of the Required Advisory Statements for Medicine Labels; or

(b) in other preparations containing 1% or less of silver.

2128. 

Sodium cromoglycate in preparations for nasal or ophthalmic use.

2129. 

Sodium nitrite for therapeutic use (except when present as an excipient).

2130. 

Squill except in preparations containing 1% or less of squill.

2132. 

Sulconazole in preparations for dermal use.

2133. 

Terbinafine for dermal use except in preparations for the treatment of tinea pedis.

2134. 

Tetrachloroethylene for human therapeutic use.

2135. 

Tetrahydrozoline.

except in preparations for the treatment of children 2 years of age or less.

2137. 

Thiabendazole for human therapeutic use.

2138. 

Tioconazole in preparations for dermal use, except in preparations for the treatment of tinea pedis.

2139. 

Tramazoline.

2139M. 

Triamcinolone in aqueous nasal sprays delivering 55 micrograms or less of triamcinolone per actuation, when the maximum recommended daily dose is no greater than 220 micrograms, for prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

2140. 

Trimeprazine when combined with one or more other therapeutically active substances in solid oral preparations when –

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day-night pack containing trimeprazine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper –

except in preparations for the treatment of children under 2 years of age.

2141. 

Triprolidine when combined with one or more other therapeutically active substances in oral preparations when –

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day-night pack containing triprolidine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper –

except in preparations for the treatment of children under 2 years of age.

2142. 

Tuaminoheptane.

2143. 

Tymazoline.

2144. 

Xylometazoline.

2145. 

Zinc chloride for human dermal use except in preparations containing 5% or less of zinc chloride.

3001. 

Adrenaline in preparations containing more than 0.02%, but not more than 1%, of adrenaline.

3002. 

Alclometasone as the only therapeutically active substance in preparations for dermal use containing 0.05% or less of alclometasone in packs containing 30g or less of such preparations.

3003. 

Aminophylline in liquid oral preparations containing 2% or less of aminophylline.

3004. 

Amorolfine for topical use except –

(a) when included in Schedule 2 ; or

(b) in preparations for the treatment of tinea pedis.

3005. 

Azatadine in oral preparations.

3006. 

Azelastine in topical eye preparations containing 0.05% or less of azelastine.

3007. 

Brompheniramine in oral preparations except –

(a) when included in Schedule 2 ; or

(b) for the treatment of children under 2 years of age.

3008. 

Buclizine in oral preparations.

3009. 

Butoconazole in preparations for vaginal use.

3010. 

Chlorbutol in preparations for human use except –

(a) when included in Schedule 2 ; or

(b) in preparations containing 0.5% or less of chlorbutol.

3011. 

Chlorpheniramine in oral preparations except –

(a) when included in Schedule 2 ; or

(b) for the treatment of children under 2 years of age.

3012. 

Ciclopirox in preparations for dermal use and for application to the nails except –

(a) when included in Schedule 2 ; or

(b) in preparations for the treatment of tinea pedis.

3013. 

Cimetidine in a primary pack containing not more than 14 days' supply.

3014. 

Clemastine in preparations for oral use.

3014M. 

Clobetasone (clobetasone-17-butyrate) as the only therapeutically active substance in preparations for dermal use containing 0.05% or less of clobetasone in packs containing 30g or less of such preparations.

3015. 

Clotrimazole in preparations for vaginal use.

3016. 

Codeine when compounded with –

(a) a single non-opiate analgesic substance in divided preparations containing 10mg or less of codeine per dosage unit and with a recommended daily dose not exceeding 60mg of codeine; or

(b) paracetamol in divided preparations containing 12mg or less of codeine per dosage unit and with a recommended daily dose greater than 60mg but not exceeding 100mg of codeine when –

(i) packed in blister or strip packaging or in a container with a child-resistant closure; and

(ii) in a primary pack containing 12 or less dosage units –

except when included in Schedule 2 .

3016M. 

Cyclizine in preparations for oral use.

3017. 

Cyproheptadine in oral preparations.

3018. 

Dexchlorpheniramine in oral preparations except –

(a) when included in Schedule 2 ; or

(b) for the treatment of children under 2 years of age.

3019. 

Diclofenac in divided preparations for oral use containing 25mg or less of diclofenac per dosage unit in a pack containing 30 or fewer dosage units except when included in Schedule 2 .

3020. 

Dihydrocodeine when –

(a) compounded with one or more other therapeutically active substances; or

(i) in divided preparations containing 10mg or less of dihydrocodeine per dosage unit; or

(ii) in undivided preparations containing 0.25% or less of dihydrocodeine; and

(b) labelled with a recommended dose not exceeding 15mg of dihydrocodeine –

except when included in Schedule 2 .

3021. 

Di-iodohydroxyquinolone (iodoquinol) for vaginal use.

3022. 

Dimenhydrinate in oral preparations except when included in Schedule 2 .

3023. 

Dimethindene in oral preparations except when supplied specifically for use, or labelled as suitable, for the sedation of children.

3024. 

Diphenhydramine in oral preparations except –

(a) when included in Schedule 2 ; or

(b) for the treatment of children under 2 years of age.

3025. 

Diphenoxylate in packs of 8 or less dosage units, each dosage unit containing 2.5mg or less of diphenoxylate and a quantity of atropine sulphate equivalent to at least 1% of the dose of diphenoxylate.

3027. 

Dithranol for therapeutic use.

3028. 

Doxylamine in oral preparations except –

(a) when included in Schedule 2 ; or

(b) for the treatment of children under 2 years of age.

3029. 

Econazole in preparations for vaginal use.

3030. 

Erythrityl tetranitrate for therapeutic use.

3031. 

Flavoxate.

3031M. 

Fluconazole in single-dose oral preparations containing 150mg or less of fluconazole for the treatment of vaginal candidiasis.

3033. 

Fluorides for human topical use –

(a) in liquid preparations containing 5 500mg/kg or less of fluoride ion, in a container with a child-resistant closure, except when included in or expressly excluded from Schedule 2 ; or

(b) in non-liquid preparations containing 5 500mg/kg or less of fluoride ion except –

(i) in preparations for therapeutic use containing 1 500mg/kg or less of fluoride ion and, when containing more than 1 000mg/kg of fluoride ion, compliant with the requirements of the Required Advisory Statements for Medicine Labels; or

(ii) in preparations for non-therapeutic use containing 1 500mg/kg or less of fluoride ion and, when containing more than 1 000mg/kg of fluoride ion, labelled with warnings to the following effect:

(A) Do not swallow;

(B) Do not use [this product/name of product] in children 6 years of age or less; or

(iii) in preparations for supply to registered dental professionals or by approval of an appropriate authority.

3038. 

Glucagon.

3039. 

Glyceryl trinitrate in preparations for –

(a) oral use; or

(b) rectal use.

3040. 

Glycopyrronium except when included in Schedule 4 .

3041. 

Hydrocortisone and Hydrocortisone acetate, but excluding other salts and derivatives, in preparations for human therapeutic use containing 1% or less of hydrocortisone –

(a) for dermal use, in packs containing 30g or less of such preparations, and containing no other therapeutically active constituent other than an antifungal substance; or

(b) for rectal use when combined with a local anaesthetic substance but no other therapeutically active constituent except an unscheduled astringent –

(i) in undivided preparations, in packs of 35g or less; or

(ii) in packs containing 12 or fewer suppositories –

except when included in Schedule 2 .

3041M. 

Ibuprofen in divided preparations, each containing 400mg or less of ibuprofen, in a primary pack containing not more than 50 dosage units when labelled –

(a) with a recommended daily dose of 1 200mg or less of ibuprofen; and

(b) not for the treatment of children under 12 years of age –

except when included in or expressly excluded from Schedule 2 .

3042. 

Inositol nicotinate.

3043. 

Isoconazole in preparations for vaginal use.

3044. 

Isosorbide dinitrate in oral preparations containing 10mg or less of isosorbide dinitrate per dosage unit.

3045. 

Ketoprofen in divided preparations for oral use containing 25mg or less of ketoprofen per dosage unit in a pack containing 30 or less dosage units.

3045M. 

Levonorgestrel for emergency post-coital contraception.

3046. 

Macrogols in preparations for oral use for bowel cleansing prior to diagnostic, medical or surgical procedures.

3047. 

Malathion in preparations for human external use except in preparations containing 2% or less of malathion.

3048. 

Mannityl hexanitrate for therapeutic use.

3049. 

Mepyramine in oral preparations.

3050. 

Methdilazine in oral preparations.

3051. 

Metoclopramide when combined with paracetamol in divided preparations, packed and labelled only for the treatment of nausea associated with migraine, in packs containing not more than 10 dosage units.

3052. 

Miconazole for human use in topical preparations –

(a) for the treatment of oral candidiasis; or

(b) for vaginal use.

3056. 

Nicotinic acid for human therapeutic use in divided preparations containing 250mg or less of nicotinic acid per dosage unit, except –

(a) in preparations containing 100mg or less of nicotinic acid per dosage unit; or

(b) nicotinamide.

3057. 

Nicotinyl alcohol except in preparations containing 100mg or less of nicotinyl alcohol per dosage unit.

3059. 

Nystatin in preparations for topical use except when included in Schedule 2 .

3059M. 

Orlistat in oral preparations for weight-control purposes containing 120mg or less of orlistat per dosage unit.

3059R. 

Oxiconazole in preparations for vaginal use.

3059X. 

Pantoprazole in oral preparations containing 20mg or less of pantoprazole for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply.

3060. 

Pheniramine in oral preparations except –

(a) when included in Schedule 2 ; or

(b) for the treatment of children under 2 years of age.

3063. 

Podophyllotoxin in preparations containing 1% or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts except when in Schedule 2 .

3064. 

Podophyllum emodi (podophyllin) in preparations containing 20% or less of podophyllin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2 .

3065. 

Podophyllum peltatum (podophyllin) in preparations containing 20% or less of podophyllin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2 .

3066. 

Prochlorperazine in divided preparations for oral use in packs containing not more than 10 dosage units for the treatment of nausea associated with migraine.

3067. 

Promethazine in oral preparations except –

(a) when included in Schedule 2 ; or

(b) in preparations for the treatment of children under 2 years of age.

3067M. 

Pseudoephedrine (other than preparations for stimulant, appetite-suppression or weight-control purposes) when supplied in a primary pack –

(a) in liquid preparations containing 800mg or less of pseudoephedrine hydrochloride (or its equivalent); or

(b) in other preparations containing 720mg or less of pseudoephedrine hydrochloride (or its equivalent).

3069. 

Salicylic acid in preparations for dermal use except in preparations containing 40% or less of salicylic acid.

3070. 

Salbutamol as the only therapeutically active substance –

(a) in metered aerosols delivering 100 micrograms or less of salbutamol per metered dose; or

(b) in dry powders for inhalation delivering 200 micrograms or less of salbutamol per dose.

3071. 

Santonin.

3073. 

Sodium phosphate in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures.

3073E. 

Sodium picosulfate in preparations for oral use for bowel cleansing prior to diagnostic medical or surgical procedures.

3074. 

Sulfacetamide in preparations for ophthalmic use containing 10% or less of sulfacetamide.

3075. 

Terbutaline as the only therapeutically active substance –

(a) in metered aerosols delivering 250 micrograms or less of terbutaline per metered dose; or

(b) in dry powders for inhalation delivering 500 micrograms or less of terbutaline per dose.

3077. 

Theophylline in liquid oral preparations containing 2% or less of theophylline.

3078. 

Tioconazole in preparations for vaginal use.

3080. 

Triamcinolone for buccal use in preparations containing 0.1% or less of triamcinolone in a pack of 5g or less.

3081. 

Trimeprazine –

(a) in solid oral preparations except when included in Schedule 2 ; or

(b) in liquid oral preparations containing 10mg or less of trimeprazine per 5mL –

except in preparations for the treatment of children under 2 years of age.

3082. 

Triprolidine in oral preparations except –

(a) when included in Schedule 2 ; or

(b) for the treatment of children under 2 years of age.

40001. 

Abacavir.

40001M. 

Abatacept.

40002. 

Abciximab.

40003. 

Acamprosate calcium.

40004. 

Acarbose.

40005. 

Acebutolol.

40006. 

Acepromazine.

40007. 

Acetanilide and alkyl acetanilides (excluding when present as an excipient) for human therapeutic use.

40008. 

Acetarsol.

40009. 

Acetazolamide.

40010. 

Acetohexamide.

40010M. 

Acetyl isovaleryltylosin.

40011. 

Acetylcarbromal.

40012. 

Acetylcholine.

40013. 

Acetylcysteine except –

(a) when included in Schedule 2 ; or

(b) in preparations for oral use when labelled with a recommended daily dose of 1g or less of acetylcysteine.

40014. 

Acetyldigitoxin.

40015. 

Acetylmethyldimethyloximidophenylhydrazine.

40016. 

Acetylstrophanthidin.

40017. 

Aciclovir except in preparations containing 5% or less of aciclovir for the treatment of Herpes labialis in packs containing 10g or less.

40018. 

Acipimox.

40019. 

Acitretin.

40020. 

Acokanthera ouabaio.

40021. 

Acokanthera schimperi.

40022. 

Aconitum spp. except –

(a) when included in Schedule 2 ; or

(b) in preparations for oral use in adults in packs containing 0.02mg or less of total alkaloids; or

(c) in preparations for dermal use in adults containing 0.02% or less of total alkaloids in packs containing 0.02mg or less of total alkaloids.

40022M. 

Acrivastine.

40023M. 

Adalimumab.

40024. 

Adapalene.

40024M. 

Adefovir.

40025. 

Adenosine for human therapeutic use in preparations for injection.

40026. 

Adiphenine.

40027. 

Adonis vernalis.

40027M. 

Adrafinil.

40028. 

Adrenaline except –

(a) when included in Schedule 3 ; or

(b) in preparations containing 0.02% or less of adrenaline.

40029. 

Adrenocortical hormones, except when separately specified in these Schedules.

40029F. 

Agalsidase.

40030. 

Aglepristone.

40030E. 

Agomelatine.

40031. 

Alatrofloxacin mesylate.

40032. 

Albendazole except –

(a) when included in Schedule 5 or 6 ; or

(b) in intraruminal implants each containing 3.85g or less of albendazole for the treatment of animals.

40033. 

Alclofenac.

40034. 

Alclometasone except when included in Schedule 3 .

40035. 

Alcuronium.

40036. 

Aldesleukin.

40037. 

Aldosterone.

40037S. 

Alefacept.

40037V. 

Alemtuzumab.

40039. 

Alendronic acid.

40040. 

Alfacalcidol.

40041. 

Alfuzosin.

40042. 

Alglucosidase.

40042M. 

Aliskiren.

40043. 

Allergens.

40044. 

Allopurinol.

40045. 

Allyloestrenol.

40046. 

Alosetron.

40047. 

Alphadolone.

40048. 

Alphaxalone.

40049. 

Alprazolam.

40050. 

Alprenolol.

40051. 

Alprostadil.

40052. 

Alseroxylon.

40053. 

Alteplase

40054. 

Altrenogest.

40055. 

Altretamine (hexamethylmelamine).

40056. 

Amantadine.

40057. 

Ambenonium chloride.

40058. 

Ambucetamide.

40059. 

Ambutonium bromide.

40060. 

Amcinonide.

40061. 

Amethocaine except –

(a) when included in Schedule 2 ; or

(b) in dermal preparations containing 2% or less of total local anaesthetic substances.

40062. 

Amifostine.

40063. 

Amikacin.

40064. 

Amiloride.

40066. 

Aminocaproic acid.

40067. 

Aminoglutethimide.

40068. 

Aminometradine.

40069. 

Aminophenazone (amidopyrine) and derivatives for the treatment of animals.

40070. 

Aminophylline except when included in Schedule 3 .

40071. 

Aminopterin.

40072. 

4-aminopyridine for therapeutic use.

40073. 

Aminorex.

40074. 

Aminosalicylic acid.

40075. 

Amiodarone.

40076. 

Amiphenazole.

40077. 

Amisometradine.

40078. 

Amisulpride.

40079. 

Amitriptyline.

40080. 

Amlodipine.

40081. 

Ammi visnaga.

40082. 

Ammonium bromide for therapeutic use.

40083. 

Amodiaquine.

40084. 

Amorolfine except –

(a) when included in Schedule 2 or 3 ; or

(b) in preparations for the treatment of tinea pedis.

40085. 

Amoxapine.

40086. 

Amoxycillin.

40087. 

Amphomycin.

40088. 

Amphotericin.

40089. 

Ampicillin.

40090. 

Amprenavir.

40091. 

Amrinone.

40092. 

Amsacrine.

40093. 

Amyl nitrite.

40094. 

Amylobarbitone when packed and labelled for injection.

40095. 

Amylocaine.

40096. 

Anabolic steroidal agents.

40097. 

Anagrelide.

40097G. 

Anakinra.

40098. 

Anastrozole.

40099. 

Ancestim.

40100. 

Ancrod and its immunoglobulin antidote.

40101. 

Androgenic steroidal agents.

40102. 

Androisoxazole.

40103. 

Androstanolone.

40104. 

Androstenediol.

40105. 

Androstenedione.

40105M. 

Anecortave.

40106. 

Angiotensin amide.

40106M. 

Anidulafungin.

40107. 

Anistreplase.

40108. 

Antazoline except when included in Schedule 2 .

40109. 

Antibiotic substances, except –

(a) when separately specified in these Schedules; or

(b) nisin.

40110. 

Antigens for human therapeutic use except when separately specified in this Schedule.

40111. 

Antihistamines not elsewhere specified in this Schedule except when included in Schedule 2 or 3 .

40112. 

Antimony for therapeutic use except when separately specified in these Schedules.

40113. 

Antisera (immunosera) for human use by injection except when separately specified in these Schedules.

40114. 

Apocynum spp.

40115. 

Apomorphine.

40116. 

Apraclonidine.

40116E. 

Apramycin.

40116J. 

Aprepitant.

40117. 

Apronal.

40118. 

Aprotinin.

40119. 

Arecoline.

40119M. 

Aripiprazole.

40120. 

Arsenic for human therapeutic use except when separately specified in these Schedules.

40121. 

Artemether.

40121E. 

Articaine.

40123. 

Aspirin –

(a) when combined with caffeine, paracetamol or salicylamide or with any of their derivatives; or

(b) for injection.

40124. 

Astemizole.

40125. 

Atamestane.

40125M. 

Atazanavir.

40126. 

Atenolol.

40127. 

Atipamezole.

40127S. 

Atomoxetine.

40128. 

Atorvastatin.

40128M. 

Atosiban.

40129. 

Atovaquone.

40130. 

Atracurium besylate.

40130M. 

Atropa Belladonna (belladonna) except when included in Schedule 2 .

40131. 

Atropine except when included in Schedule 2 .

40132. 

Atropine methonitrate.

40133. 

Auranofin.

40134. 

Aurothiomalate sodium.

40135. 

Avilamycin except –

(a) in animal feed premixes containing 15% or less of avilamycin activity; or

(b) in animal feeds containing 50mg/kg or less of avilamycin activity.

40136. 

Aviptadil.

40137. 

Avoparcin.

40137M. 

Azacitidine.

40138. 

Azacyclonol.

40139. 

Azaperone.

40140. 

Azapropazone.

40141. 

Azarabine.

40142. 

Azatadine except when included in Schedule 3 .

40143. 

Azathioprine.

40144. 

Azelaic acid except –

(a) when included in Schedule 2 ; or

(b) in preparations containing 1% or less of azelaic aid for non-human use.

40145. 

Azelastine except when included in Schedule 2 or 3 .

40146. 

Azithromycin.

40147. 

Azlocillin.

40148. 

Aztreonam.

40149. 

Bacampicillin.

40150. 

Bacitracin.

40151. 

Baclofen.

40152. 

Balsalazide.

40153. 

Bambermycin (flavophospholipol) except –

(a) when included in Schedule 6 ; or

(b) in animal feeds for growth promotion containing 50mg/kg or less of antibiotic substances.

40154. 

Bambuterol.

40155. 

Bamethan.

40156. 

Bamipine.

40157. 

Barbiturates, except when specified separately in these Schedules.

40158. 

Basiliximab.

40159. 

Becaplermin.

40160. 

Beclamide.

40161. 

Beclomethasone except when included in Schedule 2 .

40163. 

Bemegride.

40164. 

Benactyzine.

40165. 

Benazepril.

40166. 

Bendrofluazide.

40167. 

Benethamine penicillin.

40168. 

Benorylate.

40169. 

Benoxaprofen.

40170. 

Benperidol.

40171. 

Benserazide.

40173. 

Benzathine penicillin.

40174. 

Benzhexol.

40175. 

Benzilonium.

40176. 

Benzocaine except –

(a) when included in Schedule 2 ; or

(b) in dermal preparations containing 2% or less of total local anaesthetic substances; or

(c) in lozenges containing 30mg or less of total local anaesthetic substances per dosage unit.

40177. 

Benzodiazepine derivatives not elsewhere specified in these Schedules.

40178. 

Benzoyl peroxide in preparations for human therapeutic use except –

(a) when included in Schedule 2 ; or

(b) in preparations for external use containing 5% or less of benzoyl peroxide.

40179. 

Benzphetamine.

40180. 

Benzthiazide.

40181. 

Benztropine (benzatropine).

40182. 

Benzydamine except –

(a) when included in Schedule 2 ; or

(b) in preparations for dermal use.

40183. 

Benzylpenicillin.

40184. 

Bepridil.

40185. 

Beractant.

40186. 

Betahistine.

40187. 

Betamethasone.

40188. 

Betaxolol.

40189. 

Bethanechol chloride.

40190. 

Bethanidine.

40190V. 

Bevacizumab.

40191. 

Bevantolol.

40191M. 

Bexarotene.

40192. 

Bezafibrate.

40193. 

Bicalutamide.

40194. 

Bifonazole except –

(a) when included in Schedule 2 ; or

(b) in preparations for dermal use containing 1% or less of bifonazole for the treatment of the scalp; or

(c) in preparations for dermal use for the treatment of tinea pedis.

40194M. 

Bimatoprost.

40195. 

Biperiden.

40196. 

Bismuth compounds for cosmetic use except –

(a) bismuth citrate when incorporated in hair-colourant preparations in concentrations of 0.5% or less; or

(b) bismuth oxychloride.

40197. 

Bismuth compounds for human therapeutic use, except bismuth formic iodide or bismuth subiodide in dusting powders containing 3% or less of bismuth.

40198. 

Bisoprolol.

40199. 

Bivalirudin.

40200. 

Bleomycin.

40201. 

Bolandiol.

40202. 

Bolasterone.

40203. 

Bolazine.

40204. 

Boldenone (otherwise known as dehydrotestosterone).

40205. 

Bolenol.

40206. 

Bolmantalate.

40207. 

Boron, including boric acid and borax, for human therapeutic use except –

(a) in preparations for internal use containing 6mg or less of boron per recommended daily dose; or

(b) in preparations for dermal use containing 0.35% or less of boron, which are not for paediatric or antifungal use; or

(c) when present as an excipient.

40207E. 

Bortezomib.

40207M. 

Bosentan.

40208. 

Botulinum toxins for human use except when separately specified in these Schedules.

40209. 

Bretylium tosylate.

40210. 

Brimonidine.

40211. 

Brinzolamide.

40212. 

Bromazepam.

40213. 

Bromides, inorganic, for therapeutic use except when separately specified in these Schedules.

40214. 

Bromocriptine.

40215. 

Bromoform for therapeutic use.

40216. 

Brompheniramine except when included in Schedule 2 or 3 .

40217. 

Bromvaletone.

40218. 

Brugmansia spp.

40219. 

Buclizine, except when included in Schedule 3 .

40220. 

Budesonide except when included in Schedule 2 .

40221. 

Bufexamac except –

(a) in preparations for dermal use containing 5% or less of bufexamac; or

(b) in suppositories.

40222. 

Bumetanide.

40223. 

Buphenine.

40224. 

Bupivacaine.

40225. 

Bupropion.

40226. 

Buserelin.

40227. 

Buspirone.

40228. 

Busulfan.

40229. 

Butacaine.

40229M. 

Butoconazole except when included in Schedule 3 .

40229S. 

Butraconazole.

40230. 

Butyl nitrite.

40231. 

Butyl aminobenzoate except in dermal preparations containing 2% or less of total local anaesthetic substances.

40232. 

Butylchloral hydrate.

40233. 

Cabergoline.

40233E. 

Cadmium compounds for human therapeutic use.

40234. 

Calcipotriol.

40235. 

Calcitonin.

40236. 

Calcitriol.

40237. 

Calcium carbimide for therapeutic use.

40238. 

Calcium polystyrene sulphonate.

40239. 

Calotropis gigantea.

40240. 

Calotropis procera.

40241. 

Calusterone.

40242. 

Camphorated oil for therapeutic use.

40243. 

Camphotamide.

40244. 

Candesartan cilexetil.

40245. 

Candicidin.

40246. 

Canine tick antiserum.

40247. 

Cantharidin.

40248. 

Capecitabine.

40249. 

Capreomycin.

40250. 

Captodiame.

40251. 

Captopril.

40252. 

Capuride.

40253. 

Caramiphen.

40254. 

Carbachol.

40255. 

Carbamazepine.

40256. 

Carbaryl for human therapeutic use.

40257. 

Carbazochrome.

40258. 

Carbenicillin.

40259. 

Carbenoxolone for internal use.

40259E. 

Carbetocin.

40260. 

Carbidopa.

40261. 

Carbimazole.

40262. 

Carbocromen.

40263. 

Carboplatin.

40264. 

Carboprost.

40265. 

Carbromal.

40266. 

Carbutamide.

40266E. 

Carbuterol.

40267. 

Carindacillin.

40268. 

Carisoprodol.

40269. 

Carmustine.

40270. 

Carnidazole.

40271. 

Carprofen.

40272. 

Carvedilol.

40272H. 

Caspofungin.

40273. 

Cathine.

40273T. 

Cefacetrile.

40274. 

Cefaclor.

40274M. 

Cefadroxil.

40274P. 

Cefaloridine.

40274S. 

Cefamandole.

40274V. 

Cefapirin.

40274X. 

Cefazolin.

40275. 

Cefepime.

40276. 

Cefetamet.

40277. 

Cefixime.

40278. 

Cefodizime.

40279. 

Cefonicid.

40280. 

Cefoperazone.

40281. 

Cefotaxime.

40282. 

Cefotetan.

40283. 

Cefotiam.

40283M. 

Cefovecin for veterinary use.

40284. 

Cefoxitin.

40285. 

Cefpirome.

40286. 

Cefpodoxime.

40287. 

Cefsulodin.

40288. 

Ceftazidine.

40289. 

Ceftibuten.

40290. 

Ceftiofur.

40291. 

Ceftriaxone.

40292. 

Cefuroxime.

40293. 

Celecoxib.

40294. 

Celiprolol.

40296H. 

Cephaelis acuminata (ipecacuanha) except in preparations containing 0.2% or less of emetine.

40296R. 

Cephaelis ipecacuanha except in preparations containing 0.2% or less of emetine.

40297. 

Cephalexin.

40298. 

Cephalonium.

40299. 

Cefaloridine.

40300. 

Cephalothin.

40301. 

Cefamandole.

40302. 

Cefapirin.

40303. 

Cefazolin.

40304. 

Cephradine.

40305. 

Cerivastatin.

40306. 

Ceruletide.

40307. 

Cetirizine except when included in Schedule 2 .

40308. 

Cetrorelix.

40308E. 

Cetuximab.

40309. 

Chenodeoxycholic acid.

40310. 

Chloral formamide.

40311. 

Chloral hydrate except in preparations for topical use containing 2% or less of chloral hydrate.

40312. 

Chloralose except when included in Schedule 6 .

40313. 

Chlorambucil.

40314. 

Chloramphenicol.

40315. 

Chlorandrostenolone.

40316. 

Chlorazanil.

40317. 

Chlorcyclizine.

40318. 

Chlordiazepoxide.

40319. 

Chlormerodrin.

40320. 

Chlormethiazole.

40321. 

Chlormezanone.

40322. 

Chloroform for use in anaesthesia.

40323. 

4-Chloromethandienone.

40324. 

2-(4-chlorophenyl)-(1,2,4) triazolo [5,1-A] isoquinoline.

40325. 

Chloroquine.

40326. 

Chlorothiazide.

40327. 

Chlorotrianisene.

40328. 

Chloroxydienone.

40329. 

Chlorpheniramine except when included in Schedule 2 or 3 .

40330. 

Chlorphentermine.

40331. 

Chlorpromazine.

40332. 

Chlorpropamide.

40333. 

Chlorprothixene.

40334. 

Chlorquinaldol for human topical use.

40335. 

Chlortetracycline except when included in Schedule 5 .

40336. 

Chlorthalidone.

40337. 

Chlorzoxazone.

40338. 

Cholera vaccine.

40339. 

Cholestyramine (colestyramine) for human therapeutic use.

40340. 

Chymopapain for human therapeutic use.

40341. 

Ciclacillin.

40341J. 

Ciclesonide.

40342. 

Ciclopirox except when included in Schedule 2 or 3 .

40343. 

Cidofovir.

40344. 

Cilastatin.

40345. 

Cilazapril.

40346. 

Cimetidine except when included in Schedule 3 .

40346S. 

Cinacalcet.

40347. 

Cinchocaine except when included in Schedule 2

40348. 

Cinoxacin.

40349. 

Ciprofloxacin.

40350. 

Cisapride.

40351. 

Cisatracurium besylate.

40352. 

Cisplatin.

40353. 

Citalopram.

40354. 

Cladribine.

40355. 

Clanobutin.

40356. 

Clarithromycin.

40357. 

Clavulanic acid.

40358. 

Clemastine except when included in Schedule 3 .

40359. 

Clemizole.

40360. 

Clenbuterol.

40361. 

Clidinium bromide.

40362. 

Clindamycin.

40363. 

Clioquinol and other halogenated derivatives of 8-hydroxyquinoline for human topical use except when separately specified in this Schedule.

40364. 

Clobazam.

40365. 

Clobetasol.

40366. 

Clobetasone (clobetasone-17-butyrate) except when included in Schedule 3 .

40367. 

Clocortolone.

40368. 

Clodronic acid (including sodium clodronate).

40369. 

Clofazimine.

40370. 

Clofenamide.

40371. 

Clofibrate.

40372. 

Clomiphene.

40373. 

Clomipramine.

40374. 

Clomocycline.

40375. 

Clonazepam.

40376. 

Clonidine.

40377. 

Clopamide.

40378. 

Clopidogrel.

40379. 

Cloprostenol.

40380. 

Clorazepate.

40381. 

Clorexolone.

40382. 

Clorprenaline.

40383. 

Clostebol (otherwise known as 4-chlorotestosterone).

40384. 

Clotrimazole –

(a) except when included in Schedule 2 , 3 or 6 ; or

(b) in preparations for dermal use for the treatment of tinea pedis.

40385. 

Cloxacillin.

40386. 

Clozapine.

40386M. 

Cobalt for human therapeutic use except as dicobalt edetate in preparations for the treatment of cyanide poisoning.

40387. 

Codeine when compounded with one or more other therapeutically active substances –

(a) in divided preparations containing 30mg or less of codeine per dosage unit; or

(b) in undivided preparations containing 1% or less of codeine –

except when included in Schedule 2 or 3 .

40388. 

Co-dergocrine.

40389. 

Colaspase.

40390. 

Colchicine.

40391. 

Colchicum autumnale.

40392. 

Colestipol.

40393. 

Colfosceril palmitate for human therapeutic use.

40394. 

Colistin.

40395. 

Collagen in preparations for injection or implantation –

(a) for tissue augmentation; or

(b) for cosmetic use.

40396. 

Convallaria keiski.

40397. 

Convallaria majalis.

40397H. 

Copper compounds for human use except –

(a) when separately specified in these Schedules; or

(b) in preparations for human internal use containing 5mg or less of copper per recommended daily dose; or

(c) in other preparations containing 5% or less of copper compound.

40398. 

Coronilla spp.

40399. 

Corticosterone.

40400. 

Corticotrophin.

40401. 

Cortisone.

40402. 

Co-trimoxazole.

40403. 

Coumarin for therapeutic use (except when present as an excipient).

40404. 

Crystal violet for human use, except when used as a dermal marker.

40404S. 

Cuprimyxin.

40405. 

Curare.

40406. 

Cyclandelate.

40407. 

Cyclizine except when included in Schedule 3 .

40408. 

Cyclobenzaprine.

40409. 

Cyclofenil.

40410. 

Cycloheximide.

40411. 

Cyclopenthiazide.

40412. 

Cyclopentolate.

40413. 

Cyclophosphamide.

40414. 

Cyclopropane for therapeutic use.

40415. 

Cycloserine.

40416. 

Cyclosporin.

40417. 

Cyclothiazide.

40418. 

Cycrimine.

40419. 

Cymarin.

40420. 

Cyproheptadine except when included in Schedule 3 .

40421. 

Cyproterone.

40422. 

Cysteamine for human therapeutic use.

40423. 

Cytarabine.

40423E. 

Dabigatran.

40424. 

Dacarbazine.

40425. 

Daclizumab.

40425M. 

Dactinomycin.

40426. 

Dalfopristin.

40427. 

Dalteparin (includes dalteparin sodium).

40428. 

Danaparoid (includes danaparoid sodium).

40429. 

Danazol.

40430. 

Danthron for human use.

40431. 

Dantrolene.

40432. 

Dapsone.

40432E. 

Daptomycin.

40432H. 

Darbepoetin.

40432M. 

Darifenacin.

40432R. 

Darunavir.

40432V. 

Dasatinib.

40433. 

Datura spp. except –

(a) when included in Schedule 2 ; or

(b) when separately specified in this Schedule.

40433D. 

Datura stramonium (stramonium) except –

(a) when included in Schedule 2 ; or

(b) for smoking or burning.

40433H. 

Datura tatula (stramonium) except –

(a) when included in Schedule 2 ; or

(b) for smoking or burning.

40434. 

Daunorubicin.

40435. 

Deanol.

40436. 

Debrisoquine.

40437. 

Decamethonium.

40437F. 

Deferasirox.

40437M. 

Deferiprone.

40438. 

Deflazacort.

40439. 

Dehydrochloromethyltestosterone.

40440. 

Dehydrocorticosterone.

40441. 

Delavirdine (includes delavirdine mesylate).

40442. 

Dembrexine except when included in Schedule 5

40443. 

Demecarium.

40444. 

Demeclocycline.

40445. 

Deoxycortone.

40446. 

Deoxyribonuclease except –

(a) when separately specified in this Schedule; or

(b) for external use.

40446M. 

Deracoxib.

40447. 

Desferrioxamine.

40448. 

Desflurane.

40449. 

Desipramine.

40450. 

Desirudin.

40451. 

Deslanoside.

40451H. 

Desloratadine except when included in Schedule 2 .

40452. 

Deslorelin.

40453. 

Desmopressin (otherwise known as DDAVP).

40454. 

Desogestrel.

40455. 

Desonide.

40456. 

Desoxymethasone.

40456M. 

Desvenlafaxine.

40457. 

Detomidine.

40458. 

Dexamethasone.

40459. 

Dexchlorpheniramine except when included in Schedule 2 or 3 .

40460. 

Dexfenfluramine.

40461. 

Dexmedetomidine.

40462. 

Dextromethorphan (excluding its stereoisomers) except when included in Schedule 2 .

40463. 

Dextropropoxyphene in –

(a) divided preparations containing 135mg or less of dextropropoxyphene per dosage unit; or

(b) liquid preparations containing 2.5% or less of dextropropoxyphene.

40464. 

Dextrorphan (excluding its stereoisomers).

40465. 

Diamthazole.

40465M. 

Diaveridine.

40466. 

Diazepam.

40467. 

Diazoxide.

40468. 

Dibenzepin.

40468M. 

Dibotermin.

40468U. 

Dibromopropamidine for therapeutic use except when included in Schedule 2 .

40469. 

Dichloralphenazone.

40469M. 

Dichlorophen for human therapeutic use.

40470. 

Dichlorphenamide.

40471. 

Diclofenac except –

(a) when included in Schedule 2 or 3 ; or

(b) in preparations for dermal use.

40472. 

Dicloxacillin.

40473. 

Dicyclomine.

40474. 

Didanosine.

40475. 

Dienestrol.

40475H. 

Dienogest.

40476. 

Diethazine.

40477. 

Diethylcarbamazine for human therapeutic use.

40478. 

Diethylpropion.

40479. 

Difenoxin in preparations containing, per dosage unit, 0.5mg or less of difenoxin and a quantity of atropine sulfate equivalent to at least 5% of the dose of difenoxin.

40480. 

Diflorasone.

40481. 

Difloxacin.

40482. 

Diflucortolone.

40483. 

Diflunisal.

40484. 

Digitalis lanata.

40485. 

Digitalis purpurea.

40486. 

Digitoxin.

40487. 

Digoxin.

40488. 

Digoxin-specific antibody fragment F (Ab).

40489. 

Dihydralazine.

40490. 

Dihydrocodeine when compounded with one or more other therapeutically active substances –

(a) in divided preparations containing not more than 100mg of dihydrocodeine per dosage unit; or

(b) in undivided preparations with a concentration of not more than 2.5% of dihydrocodeine –

except when included in Schedule 2 or 3 .

40491. 

Dihydroergotoxine.

40492. 

Dihydrolone.

40493. 

Dihydrostreptomycin.

40493M. 

Dihydrotachysterol.

40494. 

Di-iodohydroxyquinoline (iodoquinol) except –

(a) when included in Schedule 3 ; or

(b) for human internal use.

40495. 

Diisopropylamine dichloroacetate.

40496. 

Diltiazem.

40497. 

Dimenhydrinate except when included in Schedule 2 or 3 .

40498. 

Dimercaprol.

40499. 

Dimethandrostanolone.

40500. 

Dimethazine.

40501. 

Dimethindene except when included in Schedule 3 .

40501M. 

Dimethothiazine.

40502. 

Dimethoxanate.

40503. 

Dimethyl sulfoxide for therapeutic use, except –

(a) when included in Schedule 6 ; or

(b) in in-vitro test kits.

40504. 

Dimetridazole.

40505. 

2,4-dinitrochlorobenzene for therapeutic use.

40506. 

Dinitrocresols for therapeutic use except when separately specified in these Schedules.

40507. 

Dinitronaphthols for therapeutic use except when separately specified in these Schedules.

40508. 

Dinitrophenols for therapeutic use.

40509. 

Dinitrothymols for therapeutic use.

40510. 

Dinoprost.

40511. 

Dinoprostone.

40512. 

Diperodon.

40513. 

Diphemanil except in preparations for dermal use.

40514. 

Diphenhydramine except when included in Schedule 2 or 3 .

40515. 

Diphenidol.

40516. 

Diphenoxylate in preparations containing, per dosage unit, 2.5mg or less of diphenoxylate, and a quantity of atropine sulfate equivalent to at least 1% of the dose of diphenoxylate, except when included in Schedule 3 .

40517. 

Diphenylpyraline.

40518. 

Diphtheria toxoid.

40519. 

Dipivefrin.

40520. 

Dipyridamole.

40521. 

Dirithromycin.

40521M. 

Dirlotapide.

40522. 

Disophenol.

40523. 

Disopyramide.

40524. 

Distigmine.

40525. 

Disulfiram for therapeutic use.

40526. 

Disulphamide.

40527. 

Dithiazanine except when included in Schedule 6 .

40528. 

Ditiocarb.

40529. 

Dobutamine.

40530. 

Docetaxel.

40531. 

Dofetilide.

40532. 

Dolasetron.

40533. 

Domperidone.

40534. 

Donepezil.

40535. 

Dopamine.

40536. 

Dopexamine.

40537. 

Dornase.

40538. 

Dorzolamide.

40539. 

Dothiepin.

40540. 

Doxantrazole.

40541. 

Doxapram.

40542. 

Doxazosin.

40543. 

Doxepin.

40544. 

Doxorubicin.

40545. 

Doxycycline.

40546. 

Doxylamine except when included in Schedule 2 or 3 .

40547. 

Droperidol.

40547S. 

Drospirenone.

40548. 

Drostanolone.

40548H. 

Drotrecogin.

40549. 

Duboisia leichhardtii except when included in Schedule 2 .

40550. 

Duboisia myoporoides except when included in Schedule 2 .

40550F. 

Duloxetine.

40550M. 

Dutasteride.

40551. 

Dydrogesterone.

40552. 

Econazole –

(a) except when included in Schedule 2 , 3 or 6 ; or

(b) in preparations for dermal use for the treatment of tinea pedis.

40553. 

Ecothiopate (includes ecothiopate iodide).

40554. 

Ectylurea.

40555. 

Edetic acid for human therapeutic use except –

(a) in preparations containing 0.25% or less of edetic acid; or

(b) as dicobalt edetate in preparations for the treatment of cyanide poisoning; or

(c) in contact lens preparations.

40556. 

Edoxudine.

40557. 

Edrophonium.

40557M. 

Efalizumab.

40558. 

Efavirenz.

40558M. 

Eflornithine.

40560. 

Eletriptan.

40561. 

Eltenac.

40562. 

Emepronium.

40563. 

Emetine except in preparations containing 0.2% or less of emetine.

40563M. 

Emtricitabine.

40564. 

Enalapril.

40565. 

Enestebol.

40566. 

Enflurane for therapeutic use.

40566M. 

Enfuvirtide.

40567. 

Enoxacin.

40568. 

Enoxaparin.

40569. 

Enoximone.

40570. 

Enprostil.

40571. 

Enrofloxacin.

40572. 

Entacapone.

40572M. 

Entecavir.

40573. 

Ephedra spp. except in preparations containing 0.001% or less of ephedrine.

40574. 

Ephedrine.

40575. 

Epicillin.

40575M. 

Epinastine.

40576. 

Epirubicin.

40577. 

Epitiostanol.

40577E. 

Eplerenone.

40577M. 

Epoetins.

40578. 

Epoprostenol.

40579. 

Eprosartan.

40580. 

Eptifibatide.

40581. 

Ergometrine.

40582. 

Ergot.

40583. 

Ergotamine.

40584. 

Ergotoxine.

40584E. 

Erlotinib.

40584M. 

Ertapenem.

40585. 

Erysimum spp.

40586. 

Erythromycin.

40587. 

Erythropoietin.

40587B. 

Erythropoietins except when separately specified in these Schedules.

40587H. 

Escitalopram.

40588. 

Esmolol.

40589. 

Esomeprazole.

40590. 

Estramustine.

40591. 

Estropipate (piperazine oestrone sulfate).

40592. 

Etanercept.

40593. 

Ethacrynic acid.

40594. 

Ethambutol.

40595. 

Ethamivan.

40596. 

Ethanolamine in preparations for injection.

40597. 

Ethchlorvynol.

40598. 

Ether for use in anaesthesia.

40599. 

Ethinamate.

40600. 

Ethinyloestradiol.

40600M. 

Ethionamide.

40601. 

Ethisterone.

40602. 

Ethoglucid.

40603. 

Ethoheptazine.

40604. 

Ethopropazine.

40605. 

Ethosuximide.

40606. 

Ethotoin.

40607. 

Ethoxzolamide.

40608. 

Ethyl chloride for human therapeutic use.

40609. 

Ethyldienolone.

40609M. 

Ethylhexanediol for animal use.

40610. 

Ethylmorphine when compounded with one or more other therapeutically active substances –

(a) in divided preparations containing not more than 100mg of ethylmorphine per dosage unit; or

(b) in undivided preparations with a concentration of not more than 2.5% of ethylmorphine –

except when included in Schedule 2 .

40611. 

Ethyloestrenol.

40612. 

Ethynodiol.

40613. 

Etidocaine.

40614. 

Etidronic acid (includes disodium etidronate) –

(a) for internal use; or

(b) in topical preparations except in preparations containing 1% or less of etidronic acid.

40615. 

Etilefrin.

40616. 

Etiproston.

40617. 

Etodolac.

40618. 

Etofenamate except when included in Schedule 2 .

40619. 

Etonogestrel.

40620. 

Etoposide.

40620M. 

Etoricoxib.

40621. 

Etretinate.

40621M. 

Everolimus.

40622. 

Exemestane.

40622M. 

Exenatide

40622M. 

Ezetimibe.

40623. 

Famciclovir.

40624. 

Famotidine except when included in Schedule 2 .

40625. 

Felbinac except when included in Schedule 2 .

40626. 

Felodipine.

40627. 

Felypressin.

40628. 

Fenbufen.

40629. 

Fencamfamin.

40630. 

Fenclofenac.

40631. 

Fenfluramine.

40631M. 

Fenofibrate.

40632. 

Fenoldopam.

40633. 

Fenoprofen.

40634. 

Fenoterol.

40635. 

Fenpipramide.

40636. 

Fenpiprane.

40637. 

Fenproporex.

40638. 

Fenprostalene.

40639. 

Fexofenadine except when included in Schedule 2 .

40640. 

Fibrinolysin except for external use.

40641. 

Filgrastim.

40642. 

Finasteride.

40642M. 

Firocoxib.

40643. 

Flecainide.

40644. 

Fleroxacin.

40645. 

Floctafenine.

40646. 

Florfenicol.

40647. 

Fluanisone.

40648. 

Fluclorolone.

40649. 

Flucloxacillin.

40650. 

Fluconazole except when included in Schedule 3 .

40651. 

Flucytosine.

40652. 

Fludarabine.

40653. 

Fludrocortisone.

40654. 

Flufenamic acid.

40655. 

Flumazenil.

40656. 

Flumethasone.

40657. 

Flumethiazide.

40658. 

Flunisolide.

40659. 

Flunixin meglumine.

40660. 

Fluocinolone.

40661. 

Fluocinonide.

40662. 

Fluocortin.

40663. 

Fluocortolone.

40663M. 

Fluorescein in preparations for injection.

40664. 

Fluorides in preparations for human use except when included in or expressly excluded from Schedule 2 or 3 .

40665. 

Fluorometholone.

40666. 

Fluorouracil.

40667. 

Fluoxetine.

40668. 

Fluoxymesterone.

40669. 

Flupenthixol.

40670. 

Fluphenazine.

40671. 

Fluprostenol.

40672. 

Flurandrenolone.

40673. 

Flurazepam.

40674. 

Flurbiprofen except when included in Schedule 2 .

40675. 

Fluroxene for human therapeutic use.

40676. 

Fluspirilene.

40677. 

Flutamide.

40678. 

Fluticasone except when included in Schedule 2 .

40679. 

Fluvastatin.

40680. 

Fluvoxamine.

40680K. 

Folic acid in preparations for human use for injection.

40680R. 

Folinic acid in preparations for human use for injection.

40681. 

Follicle-stimulating hormone, except when separately specified in this Schedule.

40682. 

Follitropin alpha.

40683. 

Follitropin beta.

40684. 

Fomivirsen.

40684M. 

Fondaparinux.

40685. 

Formebolone.

40686. 

Formestane.

40686K. 

Formoterol.

40686T. 

Fosamprenavir.

40686X. 

Fosaprepitant.

40687. 

Foscarnet.

40688. 

Fosfestrol (diethylstilboestrol diphosphate).

40689. 

Fosinopril.

40690. 

Fosphenytoin.

40691. 

Fotemustine.

40692. 

Framycetin.

40693M. 

Fulvestrant.

40694. 

Furaltadone.

40695. 

Furazabol.

40696. 

Furazolidone.

40696M. 

Furosemide (frusemide).

40697. 

Fusidic acid.

40698. 

Gabapentin.

40699. 

Galantamine.

40700. 

Galanthus spp.

40701. 

Gallamine.

40701M. 

Galsulfase.

40702. 

Ganciclovir.

40703. 

Ganirelix.

40704. 

Gatifloxacin.

40704M. 

Gefitinib.

40705. 

Gemcitabine.

40706. 

Gemeprost.

40707. 

Gemfibrozil.

40707M. 

Gemifloxacin.

40708. 

Gentamicin.

40709. 

Gestodene.

40710. 

Gestonorone.

40711. 

Gestrinone.

40711G. 

GHRH injectable plasmid.

40712. 

Gitalin.

40713. 

Glatiramer acetate.

40714. 

Glibenclamide.

40715. 

Glibornuride.

40716. 

Gliclazide.

40717. 

Glimepiride.

40718. 

Glipizide.

40719. 

Glisoxepide.

40720. 

Glutathione for parenteral use.

40721. 

Glutethimide.

40722. 

Glyceryl trinitrate except when included in Schedule 3 .

40723. 

Glycopyrronium in preparations for injection.

40724. 

Glymidine.

40725. 

GnRH vaccine.

40726. 

Gonadorelin.

40727. 

Gonadotrophic hormones except when separately specified in these Schedules.

40728. 

Goserelin.

40729. 

Gramicidin.

40730. 

Granisetron.

40731. 

Grepafloxacin.

40732. 

Griseofulvin.

40733. 

Growth hormone (including analogues) for human use.

40734. 

Guaiphenesin for human therapeutic use except –

(a) in oral liquid preparations containing 2% or less of guaiphenesin; or

(b) in divided preparations containing 200mg or less of guaiphenesin per dosage unit.

40735. 

Guanabenz.

40736. 

Guanacline.

40737. 

Guanethidine.

40738. 

Guanidine.

40739. 

Hachimycin.

40740. 

Haematin.

40741. 

Haemophilus influenza vaccine.

40742. 

Halcinonide.

40743. 

Halofantrine.

40744. 

Halofenate.

40744E. 

Halofuginone in preparations containing 0.1% or less of halofuginone for the treatment of animals.

40745. 

Haloperidol.

40746. 

Halothane for therapeutic use.

40747. 

Hemerocallis (Hemerocallis flava).

40748. 

Heparins for internal use except when separately specified in this Schedule.

40749. 

Hepatitis A vaccine.

40750. 

Hepatitis B vaccine.

40751. 

Hetacillin.

40752. 

Hexachlorophane in –

(a) preparations for use on infants; or

(b) other preparations except –

(i) when included in Schedule 2 or 6 ; or

(ii) in preparations containing 0.75% or less of hexachlorophane.

40753. 

Hexamethonium.

40754. 

Hexetidine for human internal use.

40755. 

Hexobendine.

40756. 

Hexocyclium.

40756E. 

Hexoprenaline.

40757. 

Histamine for therapeutic use except in preparations containing 0.5% or less of histamine.

40758. 

Homatropine.

40759. 

Human chorionic gonadotrophin except in pregnancy test kits.

40760. 

Hyaluronic acid and its polymers in preparations for injection or implantation for –

(a) tissue augmentation; or

(b) cosmetic use; or

(c) the treatment of animals.

40761. 

Hydralazine.

40762. 

Hydrargaphen.

40763. 

Hydrochlorothiazide.

40764. 

Hydrocortisone, except when included in Schedule 2 or 3 .

40765. 

Hydrocyanic acid for therapeutic use.

40766. 

Hydroflumethiazide.

40767. 

Hydroquinone (other than its alkyl ethers separately specified in this Schedule) for human therapeutic or cosmetic use except –

(a) when included in Schedule 2 ; or

(b) in hair preparations containing 1% or less of hydroquinone.

40768. 

Hydroxychloroquine.

40769. 

Hydroxyephedrine.

40770. 

Hydroxyphenamate.

40771. 

Hydroxyprogesterone.

40772. 

Hydroxystenozol.

40773. 

Hydroxyurea.

40774. 

Hydroxyzine.

40775. 

Hygromycin.

40776. 

Hyoscine except when included in Schedule 2 .

40777. 

Hyoscyamine except when included in Schedule 2 .

40778. 

Hyoscyamus niger except –

(a) when included in Schedule 2 ; or

(b) in a pack containing 0.03mg or less of total solanaceous alkaloids.

40779. 

Hypothalamic-releasing factors not elsewhere specified in this Schedule.

40779K. 

Hypromellose in preparations for injection.

40779P. 

Ibafloxacin for veterinary use.

40780. 

Ibandronic acid.

40780M. 

Ibritumomab.

40781. 

Ibufenac.

40782. 

Ibuprofen except –

(a) when included in or expressly excluded from Schedule 2 or 3 ; or

(b) in preparations for dermal use.

40783. 

Ibuterol.

40784. 

Ibutilide.

40785. 

Idarubicin.

40786. 

Idoxuridine except in preparations containing 0.5% or less of idoxuridine for dermal use.

40786M. 

Idursulfase.

40787. 

Ifosfamide.

40788. 

Iloprost.

40788H. 

Imatinib.

40788S. 

Imidapril.

40789. 

Imiglucerase.

40790. 

Imipenem.

40791. 

Imipramine.

40792. 

Imiquimod.

40793. 

Immunoglobulins for human parenteral use except when separately specified in these Schedules.

40794. 

Indapamide.

40795. 

Indinavir.

40796. 

Indomethacin, except when included in Schedule 2 .

40797. 

Indoprofen.

40798. 

Indoramin.

40799. 

Infliximab.

40800. 

Influenza and coryza vaccines –

(a) for parenteral use; or

(b) for nasal administration.

40800R. 

Insulin-like growth factor I.

40800U. 

Insulin-like growth factors except when separately specified in this Schedule.

40801. 

Insulins.

40802. 

Interferons.

40803. 

Interleukins except when separately specified in these Schedules.

40804. 

Iodothiouracil.

40805. 

Ipratropium except when included in Schedule 2

40805M. 

Ipriflavone.

40806. 

Iprindole.

40807. 

Iproniazid.

40808. 

Irbesarten.

40809. 

Irinotecan.

40810. 

Iron compounds in injectable preparations for human use.

40811. 

Isoaminile.

40812. 

Isoamyl nitrite.

40813. 

Isobutyl nitrite.

40814. 

Isocarboxazid.

40815. 

Isoconazole except when included in Schedule 2 , 3 or 6 .

40816. 

Isoetarine.

40817. 

Isoflurane for therapeutic use.

40818. 

Isometheptene.

40819. 

Isoniazid.

40820. 

Isoprenaline.

40821. 

Isoprinosine.

40822. 

Isopropamide except when included in Schedule 2 .

40823. 

Isosorbide dinitrate except when included in Schedule 3 .

40824. 

Isosorbide mononitrate.

40825. 

Isotretinoin.

40826. 

Isoxicam.

40827. 

Isoxsuprine.

40828. 

Isradipine.

40829. 

Itraconazole.

40829K. 

Ivabradine.

40830. 

Ivermectin –

(a) for human use; or

(b) for the treatment of mange in dogs.

40830M. 

Ixabepilone.

40831. 

Kanamycin.

40833. 

Ketanserin except in topical preparations that –

(a) contain 0.5% or less of ketanserin; and

(b) are for the treatment of animals.

40834. 

Ketazolam.

40835. 

Ketoconazole except –

(a) when included in Schedule 2 ; or

(b) in preparations for dermal use containing 1% or less of ketoconazole for the treatment of the scalp; or

(c) in preparations for dermal use for the treatment of tinea pedis.

40836. 

Ketoprofen except –

(a) in preparations for dermal use; or

(b) when included in Schedule 3 .

40837. 

Ketorolac (includes ketorolac trometamol).

40838. 

Ketotifen except when included in Schedule 2 .

40839. 

Khellin.

40840. 

Kitasamycin except –

(a) when included in Schedule 5 ; or

(b) in animal feeds for growth promotion containing 100mg/kg or less of antibiotic substances.

40841. 

Labetalol.

40842. 

Lacidipine.

40843. 

Lamivudine.

40844. 

Lamotrigine.

40845. 

Lanatosides.

40845S. 

Lanreotide.

40846. 

Lansoprazole.

40846F. 

Lanthanum for therapeutic use.

40846J. 

Lapatinib.

40846M. 

Laronidase.

40846R. 

Laropiprant.

40847. 

Latamoxef.

40848. 

Latanoprost.

40849. 

Laudexium.

40850. 

Lauromacrogols in preparations for injection except –

(a) when present as an excipient; or

(b) when separately specified in these Schedules.

40851. 

Lead for human therapeutic use.

40852. 

Lefetamine.

40853. 

Leflunomide.

40853M. 

Lenalidomide.

40854. 

Lenograstim.

40855. 

Lepirudin.